Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scrip Team

Set Alert for Articles By Scrip Team

Latest From Scrip Team

Coronavirus Update: FDA Fast-Tracks Blood Plasma Trials, Novavax Closes In On Vaccine Start

As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.

Coronavirus COVID-19 Infectious Diseases

Coronavirus Update: BMS Expands Medicine Program, Cancer Research UK Cuts Funding

Bristol-Myers Squibb is to give away more medicines to uninsured US patients, Cancer Research UK tells of funding hardship, Oxford Biomedica joins a consortium to rapidly develop a vaccine, while a Korean company works on a stem cell therapy.

Coronavirus COVID-19 Infectious Diseases

Coronavirus Update: Inovio Begins Phase I Trials of DNA Vaccine, Fast-Track Drug Dialogue Continues

Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?

Coronavirus COVID-19 Infectious Diseases

The 2020 Scrip Awards Is Open For Entries

Entries for the Scrip Awards are now open. Now in their 16th year, the Awards seek to reward the outstanding achievements of the pharmaceutical, biotech and allied industries in improving human health and will take place in London on 2 December.

Companies Commercial

Coronavirus Update: UK Calls For COVID-19 Patients To Join Trials

GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.

Coronavirus COVID-19 Clinical Trials

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.

See All
UsernamePublicRestriction

Register